MDxHealth (MDXH) Cash & Equivalents (2020 - 2026)

MDxHealth has reported Cash & Equivalents for 8 years, with the latest figure at $43.2 million in Q1 2026.

• Quarterly Cash & Equivalents fell 34.29% year-over-year to $43.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.2 million (down 34.29% YoY) and the FY2025 annual result came in at $46.8 million, changed 0.0% from the prior year.
• Cash & Equivalents advanced to $43.2 million in Q1 2026 per MDXH's latest filing, from $29.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $65.7 million in Q1 2025 and troughed at $33081.0 in Q2 2025.
• A 5-year average of $33.0 million and a median of $32.4 million in 2023 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 353.1% in 2025, down 99.85% in 2025.
• Over 5 years, Cash & Equivalents stood at $15.5 million in 2022, then soared by 44.36% to $22.4 million in 2023, then soared by 109.11% to $46.8 million in 2024, then sank by 37.96% to $29.0 million in 2025, then surged by 48.64% to $43.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $43.2 million, $29.0 million, and $32.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.